PRPH files 8-K on Q3 2025 earnings and sets Nov. 19 call

Rhea-AI Filing Summary

ProPhase Labs, Inc. filed an 8-K reporting that it issued a press release announcing its financial results for the third quarter ended September 30, 2025. The company is also hosting a conference call on November 19, 2025 at 2:00 p.m. Eastern Time to discuss these results and provide an update on corporate developments. The filing includes forward-looking statements, notably about ProPhase Labs’ ability to regain compliance with Nasdaq listing standards or obtain additional time to do so, highlighting ongoing attention to its exchange compliance status.

Insights

Equity Analyst

Routine 8-K furnishes Q3 2025 results release and flags Nasdaq compliance focus.

The 8-K from ProPhase Labs (PRPH) primarily serves as a notice that detailed financial results for the quarter ended September 30, 2025 are contained in a separate press release furnished as Exhibit 99.1. Because the financial tables and metrics are in the exhibit, this report itself does not present revenue, earnings, or margin figures for independent evaluation.

The company is holding a results conference call on November 19, 2025 at 2:00 p.m. Eastern Time, which is a standard step to discuss performance and corporate developments. The forward-looking statement section explicitly references the company’s ability to regain compliance with Nasdaq listing standards or receive additional time, indicating that exchange compliance is an active consideration, though no specific deficiency details are repeated here.

Since this report only furnishes information and does not amend guidance or disclose quantified surprises, its impact depends on the underlying numbers and commentary in Exhibit 99.1 and on any subsequent Nasdaq-related updates in later filings.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0000868278 0000868278 2025-11-19 2025-11-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 19, 2025

PROPHASE LABS, INC.

(Exact name of Company as specified in its charter)

Delaware		000-21617		23-2577138
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

626 RXR Plaza, 6th Floor Uniondale, New York		11556
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (516) 989-0763

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Exchange Act:

Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
Common Stock, par value $0.0005		PRPH		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operation and Financial Condition.

On November 19, 2025, ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.

As previously announced, the Company will conduct a conference call today, Wednesday, November 19, 2025, at 2:00 p.m. (Eastern Time) to discuss its financial results and provide an update on corporate developments.

The information contained in Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Current Report on Form 8-K other than statements of historical fact are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the Company’s ability to regain compliance with Nasdaq listing standards or receive additional time from Nasdaq to regain compliance if necessary. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and the negative of such terms or other similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements are based on the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this Current Report on Form 8-K, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

No.		Description
99.1		Press Release dated November 19, 2025, ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ProPhase Labs, Inc.
	By:	/s/ Ted Karkus
		Ted Karkus
		Chairman of the Board and Chief Executive Officer

Date: November 19, 2025

FAQ

What did ProPhase Labs (PRPH) announce in this 8-K filing?

ProPhase Labs announced that it issued a press release reporting its financial results for the third quarter ended September 30, 2025, which is furnished as Exhibit 99.1.

Which period do the ProPhase Labs Q3 2025 results cover?

The results discussed in the press release and referenced in the 8-K cover the third quarter ended September 30, 2025.

Is ProPhase Labs hosting an earnings conference call for Q3 2025?

Yes. ProPhase Labs is conducting a conference call on November 19, 2025 at 2:00 p.m. Eastern Time to discuss its Q3 2025 financial results and provide a corporate update.

Does this ProPhase Labs 8-K mention Nasdaq listing compliance?

Yes. The forward-looking statements section includes statements about ProPhase Labs’ ability to regain compliance with Nasdaq listing standards or receive additional time from Nasdaq to regain compliance.

Are the Q3 2025 financial results in the body of the 8-K or an exhibit?

The detailed Q3 2025 financial results are contained in the press release furnished as Exhibit 99.1; the 8-K itself describes and furnishes, but does not detail, those results.

Is the information in Items 2.02 and 7.01 treated as filed or furnished?

The information in Items 2.02 and 7.01, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act, except if specifically incorporated by reference elsewhere.